SEARCH VEGSOURCE:

 

 

Follow Ups | Post Followup | Back to Discussion Board | VegSource
See spam or
inappropriate posts?
Please let us know.
  




From: TSS (216-119-139-20.ipset19.wt.net)
Subject: CJD Blood Test Patent Filed by Chronix Biomedical; New Test to Address Blood Transfusion and Surgical Safety Markets
Date: October 12, 2004 at 7:02 am PST

-------- Original Message --------
Subject: CJD Blood Test Patent Filed by Chronix Biomedical; New Test to Address Blood Transfusion and Surgical Safety Markets
Date: Tue, 12 Oct 2004 09:03:42 -0500
From: "Terry S. Singeltary Sr."
Reply-To: Bovine Spongiform Encephalopathy
To: BSE-L@UNI-KARLSRUHE.DE


October 12, 2004 09:02 AM US Eastern Timezone

CJD Blood Test Patent Filed by Chronix Biomedical; New Test to Address
Blood Transfusion and Surgical Safety Markets

BIOWIRE2K


SAN JOSE, Calif.--(BUSINESS WIRE)--Oct. 12, 2004--Chronix Biomedical
announced today that it has filed a patent application for a diagnostic
test that will help safeguard the blood supply, healthcare workers and
patients. The patent application is for the detection of abnormal
genetic material associated with Creutzfeldt-Jakob Disease (CJD), the
human equivalent of "mad cow disease" or bovine spongiform
encephalopathy (BSE). Blood donors in the U.S. are currently screened
only with a written questionnaire; there is no blood test for CJD, which
is 100% fatal. The Chronix test was developed to meet the public health
need to halt the spread of CJD through the blood supply.

Currently, confirmed diagnosis of CJD is possible only after death (post
mortem) at autopsy. Post mortem diagnosis severely restricts development
of tests to protect blood collected for transfusion, a newly-described
route of transmission of CJD and vCJD (variant Creutzfeldt-Jakob
Disease), the human form of the disease linked to exposure to animals
with mad cow disease. The second known case of transfusion-related vCJD
was recently reported in a man in the United Kingdom (Peden, A.H. et
al., The Lancet 364:527, August 7, 2004).

The Chronix CJD test uses the same technology for which Chronix was
issued a patent in 2002 for its ability to detect genetic material in
the liquid portion of blood (serum or plasma). In chronic diseases, the
genetic material detected by the Chronix technology is referred to as
circulating nucleic acids (CNA).

The first commercial application of CNA detection is the Chronix
Goettingen Living Test for BSE-Susceptibility (the "GLT"). Results from
an in-house clinical trial of the GLT were presented September 15, 2004
in Tokyo, Japan, at the International Society for Animal Genetics.

Chronix Biomedical will initiate discussions with corporate partners to
assist in bringing this new CJD test to market.

Chronix Biomedical is a privately-held functional genomics company with
offices in San Jose, CA, USA, and Goettingen, Germany. For more
information, visit www.chronixbiomedical.com
or call Mr. John DiPietro at
408-441-2072.

Contacts

Chronix Biomedical
John DiPietro, 408-441-2072


http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20041012005580&newsLang=enTSS

http://www.chronixbiomedical.com/

http://www.chronixbiomedical.com/theglt.htm

TSS






Follow Ups:



Post a Followup

Name:
E-mail: (optional)
Subject:

Comments:

Optional Link URL:
Link Title:
Optional Image URL: